



## **Quanta to Exhibit at the BRS Conference 2017**

**Alcester, Warwickshire, UK, 21 April 2017:** Quanta Dialysis Technologies Ltd (“Quanta” or the “Company”), a medical device company providing innovative haemodialysis solutions for the clinic and the home, today announces that the Company will be exhibiting at the BRS Conference 2017, which runs from 26 to 28 April 2017, at the David Ross Sports Village, Nottingham University, UK.

At the conference, Quanta will present a poster that will report on the results of the first 660 treatments completed using SC+ in the UK at Nottingham University Hospitals, Guy’s and St. Thomas’ Hospital and Queen Elizabeth Hospital, Birmingham.

Full details of the poster presentations are as follows:

**Title:** Assessment of the Safety, Efficacy and Usability of the Quanta SC+ Haemodialysis System  
**Number:** P089  
**Authors:** Dr. Charlotte Bebb, Dr. Cormac Breen, Dr. Clara Day, John E. Milad, Peter Hoyer, Andrew Gardner and Gerard Harper

In addition, Quanta will be hosting a booth, C4, where it will be showcasing its easy-to-use, compact, haemodialysis system, SC+, which is designed to support patients across the continuum of care from the clinic to the home.

If you would like to arrange a meeting with Quanta at the conference, please contact [enquiries@quantadt.com](mailto:enquiries@quantadt.com).

**-ENDS-**

**For more information about Quanta, please contact:**

**Quanta**

John E. Milad,  
Chief Executive Officer

T: +44 (0)1789 400043  
E: [enquiries@quantadt.com](mailto:enquiries@quantadt.com)

**Consilium Strategic Communications**

Amber Fennell / Matthew Neal / Lindsey Neville

T: +44 (0)203 709 5708  
E: [quanta@consilium-comms.com](mailto:quanta@consilium-comms.com)

**About SC+**

SC+ supports patients across the continuum of care from the clinic to the home. It is the only easy-to-use, compact, haemodialysis system offering high performance comparable to conventional devices and compatible with traditional treatment regimens used in-centre. The technology behind SC+ is based on an innovative and unique design that incorporates all fluid management activities onto a single-use disposable cartridge. This cartridge-based design is intended to reduce downtime, simplify treatment complexity and reduce the risk of contamination. SC+ has regulatory approval in Europe (CE Mark) and is currently being used to treat patients in the UK.

**About Quanta**

Quanta aims to improve the lives of dialysis patients by providing advanced haemodialysis solutions for use in the clinic and the home. The Company's lead product SC+ provides performance, flexibility and convenience to empower dialysis patients to regain control of their lives. Founded in 2008 and based in Alcester, UK, Quanta has attracted funding from a group of leading investors including: Stage Capital/NBGI Ventures, Wellington Partners, Seroba, b-to-v Partners, ALIAD, Seventure Partners and Kuwait Life Sciences Company, as well as IMI plc.

For more information, please visit: [www.quantadt.com](http://www.quantadt.com).